Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer

The requested reference [b1f7a6e4f230db1e02e5fd1353224ca66c367e1d] no longer exists in our database. It has been replaced by the current reference: [114569aa129338f3fb4267b373f44cac317a0414]

Authors
Category Primary study
JournalCANCER RESEARCH
Year 2023
This article has no abstract
Epistemonikos ID: bcf0d0fc071e7d12b7aa63797c30a0b78affee77
First added on: Feb 15, 2025